Agoracom Blog Home

Archive for the ‘PRIMO Nutraceuticals Inc.’ Category

Primo Nutraceuticals $PRMO.ca Partner To Sell Goods Via Walmart $WMT $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 11:12 AM on Friday, December 11th, 2020
  • Celebrity skincare and health and wellness brand Marianna Naturals Corp. is pleased to announce that they have been approved as a seller by the Walmart Marketplace.
  • The company received the greenlight on November 24 th , 2020 featuring their products on Walmart.ca

MONTREAL, Dec. 11, 2020 – (MARIANNA NATURALS CORP.) Celebrity skincare and health and wellness brand Marianna Naturals Corp. is pleased to announce that they have been approved as a seller by the Walmart Marketplace. The company received the greenlight on November 24 th , 2020 featuring their products on Walmart.ca

Marianna Naturals Corp. has been working strenuously behind the scenes over the course of the last few weeks with the intent of increasing its retail partnerships that will drive revenue for the company. With Walmart.ca as a global leader in e-commerce and innovation, and with their e-commerce site reaching over 900,000 daily visits by Canadians , the company is extremely excited to be featured in their marketplace. A total of 39 Marianna Naturals branded products over 4 different categories, are currently listed and live on the site and can be purchased here: https://www.walmart.ca/search?q=marianna%20naturals

The Walmart Marketplace is an online store where professional sellers require approval and exceptional customer service prior to inclusion on the e-commerce platform. “This is a major milestone for us. It gives the company a massive opportunity to rapidly increase sales, targeting millions of Canadians that shop online on-a-daily basis. We believe that our beauty and cosmetic products will stand out as the go-to brand for all-natural skincare,” says Joel DeBellefeuille, Co-Founder & CEO of Marianna Naturals Corp.

Marianna Naturals’ products are also featured in Faire.com a wholesale marketplace for retailers & brands; as well as Etsy.com , Boutsy.com , Tundra.com and Beautykitchenonline.com

With COVID-19 ravaging the world and cutting the revenue from companies due to lack of foot traffic in retail stores, Marianna Naturals believes that a strong online presence throughout various online stores and marketplaces, will ultimately be the norm going forward, in-order-for brands to succeed.

Placement of the company’s skincare and beauty products in the Walmart Marketplace, will increase the company’s public visibility considering their go-public strategy in the coming months through Statutory Plan of Arrangement with their partner company Primo Nutraceuticals Inc. (C: PRMO) a listed company on the CSE (Canadian Securities Exchange). A previous press release discussing the arrangement can be viewed here: https://mariannacorp.com/blog/2020/05/04/primo-nutraceuticals-inc-signs-definitive-agreement-with-celebrity-brand-beauty-kitchen

About Marianna Naturals Corp.
Marianna Naturals Corp. and Beauty Kitchen manufactures fresh handmade CBD & non-CBD beauty care, personal care, and cosmetics products, which was born from the hugely popular Beauty Kitchen YouTube series. The founder, Heather Marianna, a bubbly social media personality, translated her passion for looking and feeling her absolute best into the development of her all-natural beauty and skincare product line. Beauty Kitchen’s founder and CEO, Heather Marianna, skyrocketed in popularity with the launch of her Beauty Kitchen YouTube series in 2012 where she showcased simple, do-it-yourself beauty recipes made with common kitchen household ingredients. The series generated a powerful following of more than 4 million viewers. Beauty Kitchen is regularly featured in: Forbes, The Source, MTV, Bravo, The New York Post, People, Flipsnack, Vegas, Star Magazine, Radar Online and many more media outlets with a large following of celebrities who use their products. For more information visit: www.mariannacorp.com

Contacts

Joel DeBellefeuille, Co-Founder, Chief Executive Officer
E. [email protected] Tel. 514-434-2640
For media inquiries: [email protected] Investors: [email protected]

Shop: www.marianna.ca

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise.

No regulatory authority has approved or disapproved the information contained in this news release.

6 Small Cap Stocks That Are Providing Real Products and Solutions In The Fight Against #Coronavirus #COVID19 $DM.ca $CBDT.ca $INNO.ca $KNR.ca $MTRX.ca $PRMO.ca

Posted by AGORACOM-JC at 12:18 PM on Thursday, November 12th, 2020
What do you call the disease caused by the novel coronavirus? Covid-19

The devastation and destruction of Coronavirus COVID-19 is well documented and doesn’t need much repeating here. 

What we do know is that COVID-19 has created global demand for highly specialty products required to protect, test, detect and defend as many people as possible. 

Moreover, given its persistence and the potential for a 2nd wave around the world, governments and businesses both big and small are now in need of solutions that go beyond locking down economies by helping them stay open, generate revenue, keep people employed … all while keeping them safe.

There are no magic bullets.  COVD-19 didn’t exist 12 months ago, so there are no established or incumbent leaders.  This has created an opportunity for small but nimble companies with high-tech expertise to adapt their products as solutions in one of the many verticals that require help fighting COVID-19.

Here are 6 small-cap companies (in alphabetical order) that have provided real solutions to helping the fight against COVID-19.

Datametrex AI Limited (DM:TSXV) (D4G:FSE) (DTMXF: OTC )an AI and Machine learning company was well positioned with deep roots in South Korea to make the ultimate pivot to Covid-19 test kit distribution.  When the Canadian Government came calling for assistance in importing and distributing COVID-19 test kits, Datametrex stepped up to the task thanks to its security clearances already in place in both countries.

Since then, the company has signed multiple multi-million dollar Covid-19 test kit supply agreements with mining companies, a $20M CAD agreement with the television and film industry and various educational institutions.  This is in addition to lucrative AI contracts with various levels of government and enterprise level customers such as LOTTE Group, the fifth-largest conglomerate in Korea with annual revenues of approximately $60B USD.

REVENUE $CAD

Q1 + 62% To $809,000

Q2 + 419% To $1,954,000

TOTAL Q1 AND Q2

REVENUE     $2.8M vs $875K = +220%

GROSS PROFIT $1.2 vs $739K = +62%

Given the speed of incoming contracts, the quarterly financials don’t reflect deals done during the third quarter. Here’s just a few;

  • Datametrex Expands Distribution of Film and Television Coronavirus Testing Across Canada (October 27, 2020)
  • Expands to Toronto Film Production Company for COVID-19 Testing Solutions (September 30, 2020)
  • $20M Supply Agreement With Major Worldwide Media & Entertainment Company for COVID-19 (September 24, 2020)
  • Received Third COVID-19 Order from TV Production Company (September 21, 2020)
  • Received  COVID-19 Test Kits Order for $1.6M From a Canadian Mining Company (September 3, 2020)

··      The company has also experienced robust demand for related services. Datametrex entered into a sales agreement with 7-Eleven Korea for Robotic Process Automation infrastructure (RPA) in order to automate certain business processes.

The global RPA market size is expected to reach $7.2 billion by 2025, rising at a market growth of 32.6% CAGR during the forecast period. RPA is the technology that enables anyone to configure computer software today, or a “robot” to replicate and incorporate the actions of a person working within digital systems to conduct a business process.

For more information, please visit the Datametrex AI hub on AGORACOM.

Empower (CBDT: CSE) (EPWCF:OTCQB) (8EC:Frankfurt) is a vertically integrated, multi-state operator of medical clinics with a database of over 165,000 patients, a database that almost every medical cannabis and CBD company would kill for …. but that’s not all. In an effort to combat COVID-19 the company’s physician staffed clinics have are also generating significant revenue and growth as follows:  

  • Increased CBD treatments from patients suffering increased anxiety;
  • Covid-19 Testing for individuals and families
  • Covid-19 Testing for local businesses and employees 
  • Covid-19 Testing for enterprise level organizations across the country 
  • Empower Clinics and Loop Insights Combine COVID-19 Testing Expertise With Venue Tracing To Create First Ever “Travel Bubble” Solution For Global Travel Industry Set To Lose $3.3 Trillion
  • Acquisition of an 8,000 sq ft lab in Dallas that can process 4,000 COVID-19 RT-PCR tests per day. RT-PCR tests are considered the gold standard of COVID-19 testing

How significant is this acquisition that only closed a couple of weeks ago? At the lowest price of $USD 80 per test and operating on just 1,000 tests per day, the clinic would deliver $USD 80,000 in revenue PER DAY.

Patient Visits

  • Q1 + 377% To 5,717
  • Q2 + 56% To 6,696

Revenues $USD

  • Q1 + 416% To $790,000 (NO COVID)
  • Q2 + 56% To $923.000

TOTAL Q1 AND Q2

  • REVENUE                 $1.7M vs $745K         = + 130%
  • PATIENTS                 12,400 vs 5,500           = + 125%
  • NET LOSS                 $920K vs 1.85M         = – 50% 

Empower has now delivered growth in 4 successive financial reports (Q4, FY 2019, Q1 and Q2), so it is safe to say that superstar CEO Steve McAuley can officially claim victory on the turnaround he inherited in 2019. 

Oh, and did we mention that CEO Steven McAuley is Six Sigma certified under the quality initiative of legendary GE (General Electric) Chairman Jack Welch? We’ve never seen a Six Sigma certified CEO in the Canadian small cap markets. Never.  Which explains how McAuley has been able to guide Empower Clinics through the most disruptive retail environment in recent history and turn it into significant growth. 

For more information about the company, please check out the Empower HUB on AGORACOM.

Innocan Pharma Corporation (INNO: CSE) (IP4:FSE) is an Israeli based company developing the pharmaceutical guided missile to defeat coronavirus lung infections. The company specializes in the development of new drug platforms which combine unique properties of Cannabinoids.

Innocan, together with Tel Aviv University are developing new, revolutionary exosome based technology (CLX), loaded with cannabidiol (CBD) targeting the coronavirus infected lung cells.

Why is this significant?

CLX may hold the potential to provide anti-inflammatory properties and assist in the recovery of infected lung cells. It is expected to be administrated by inhalation, CLX will be tested on a variety of lung infections focusing on patients infected by the coronavirus disease.

Superior Management Team

More than just lip service, Innocan has a world class management team to make this happen.

In the small cap world, the jockey(s) that drive the horse are just as important as the horse itself.  The Innocan Leadership Group Is Incomparable In The Small Cap World, Comprised Of Leading Israeli Pharmaceutical Executives including:

Executive Chairman (Ron Mayron) was the CEO Of Teva Israel, one of the largest generic pharmaceutical companies in the world

Co-Founder & VP Business Development (Yoram Drucker) was the Founder of 2 NASDAQ Companies (Pluristem & Brainstorm)

Chief Technology Officer (Nir Avram) is a former member of the pharma innovation team at Perrigo, producer of OTC consumer goods and specialty pharma.

Chief Executive Officer (Iris Bincovich) has a proven track record in opening global markets, having managed hundreds of successful transactions in OTC, cosmetics and dermatology.

While the Company develops their pharmaceutical solution, Innocan has a portfolio of patent-pending and launch ready consumer health products that are already commercializing around the world as follows:

CONSUMER RETAIL – DERMA COSMETICS – A premium derma cosmetics brand, manufacturing has commenced with distribution agreements in place.

OVER THE COUNTER (OTC) PRODUCTS FOR PAIN RELIEF – patent-pending CBD pain relief brand received FDA technical validation.

Global Manufacturing / Distribution Agreements

To support this global growth, Innocan already has the following relationships in place:

Endless Sky Inc. a Canadian large scale Cannabis extractor (Manufacturing and Distribution – Canada)

Swiss CBD provider Cloud 9 Switzerland LLC (Distribution – Italy and Switzerland)

Active Therapeutics Ltd of Lancashire, United Kingdom (Distribution – UK and Ireland markets)

For more information about the company, please check out the Innocan Pharma Corporation hub on AGORACOM.

Kontrol Energy is the Google NEST of smart building technology, with a Blue Chip client base to prove it with the likes of Beyond Meat, Toyota, Oxford, Telus and Brookfield to name a few.

As a result, Kontrol is already achieving commercial success as follows:

·         Q1 $2.3M

·         Q2 $2.7M

TOTAL Q1 AND Q2

  • REVENUE                 $5M
  • GROSS PROFIT        $2.7M

ADAPTING CORE TECH TO PROVIDE BLUE CHIP CUSTOMERS WITH REAL-TIME AIR DETECTION OF COVID-19 IN COMMERCIAL BUILDINGS

As a result of the COVID-19 pandemic and the needs of its blue chip customer base, Kontrol is adapting its core technologies team to development and commercialize its Kontrol BioCloud® analyzer, a wall-mounted technology which detects the presence of COVID-19 in the air of commercial buildings and triggers an alert system to provide real time notifications.

GEARING UP PRODUCTION FOR UP TO 20,000 UNITS PER MONTH

Initial expectations, based on lab testing completed to date, is that BioCloud will be effective in small to medium space settings with 3 or more people, and therefore would be suitable for areas such as classrooms, offices, airplanes, trains, buses, long-term care facilities and hospitals. The company is currently building a global supply chain with the goal of being able to supply 20,000 units per month.

The implications of the Kontrol BioCloud® analyzer could be enormous and could have a major impact on the global economy. Paul Ghezzi, CEO of Kontrol Energy has received calls from interested parties spanning the entire globe. In addition, mainstream media has taken notice:

Early tests suggest new Canadian technology could detect the coronavirus in the air Read More

Canadian firm develops tech to ‘detect COVID-19 in the air’; stock doubles Read More.

Kontrol Energy’s BioCloud Featured By Singapore’s IBI Times Read More

CSA APPROVAL RECEIVED ON NOVEMBER 5TH

On Novebmer 5th, KNR announced receipt of CSA standards approval for its BioCloud® technology.

“This is another important milestone for Kontrol and represents the continuing advancement of the BioCloud® technology,” says Paul Ghezzi, CEO Kontrol. “CSA is a Canadian standard for safety and is also accepted in jurisdictions outside Canada. In addition to CSA we continue to work on other important regional certifications including UL and CE for the United States and European markets respectively.”

UL STANDARDS APPROVAL RECEIVED NOVEMBER 12TH

“We continue to execute on the important milestones for commercialization of BioCloud,” says Paul Ghezzi, CEO of Kontrol. “With CSA and UL we now have standards approval that covers Canada, the United States and various other global regions. We continue to work towards CE standards certification which is primarily for the European market.”

DISCLAIMER: The Company has not made any express or implied claims that its product has the ability to eliminate, cure or contain the COVID-19 (or SARS-2 Coronavirus).

For more information about the company, please check out the Kontrol Energy hub on AGORACOM.

Loop Insights (MTRX:TSXV)(RACMF:OTCQB) was already a leading provider of contactless solutions and artificial intelligence (“AI”) to the brick and mortar space prior to the arrival of COVID-19.

Over the last few months Loop has adapted its contactless platform to also provide contact tracing and real-time testing to large venues and businesses.  More than just lip service, Loop has already announced significant partnerships and news with the likes of:

TELUS  

Loop was recently accepted into the TELUS IoT Marketplace for national sales and marketing to TELUS business Customers

Andrew Turner, TELUS VP Strategic Operations,

“By partnering with innovative and leading IoT development companies, such as Loop, we’re ensuring that our customers have access to some of the most advanced IoT business solutions in the world.” 

AMAZON 

On October 29th, the Company announced that Amazon Web Services (AWS) and Loop Insights would be hosting an interactive webinar to showcase the Company ‘ s Venue Tracing Solution to a global audience of businesses to learn about the technical, security, privacy, and commercial aspects of Loop ‘ s Venue Tracing Platform. 

The invitees were from industries including but not limited to: 

  • Airlines
  • Venue Owners
  • Sports & Entertainment
  • Telecom
  • Government

How did the webinar go?  On October 30th Loop announced Early Response To Amazon Web Services And Loop Insights Showcase Of Loop Venue Tracing Solution To Global Audience Indicates Great Success

The presentation ended at approximately 1:15 PM EST, and by 8:00 PM EST Loop had received over 100 direct inquiries from enterprise-level attendees spanning many different industries and countries. Loop Insights anticipates many more direct inquiries to be received in the coming days.

Loop Insights CEO Rob Anson:

“We knew going into the webinar that interest in our Contactless Platform and Solutions was very high given the high-level nature of clients we had already announced leading up to it. These attendees, many of whom represent household name entities, were looking to us for solutions that can protect people, instill confidence in their customers and get their enterprises moving once again. Nonetheless, the response to the demonstration of our Contactless Venue Tracing Platform was simply incredible and even surpassed our expectations. We are optimistic that Loop Insights is establishing an identity as a global force in the contactless space and believe the responses will lead to significant business for Loop. We can’t thank Amazon Web Services enough for their continued support and partnership.”

In addition to these successes, Loop stated that its Venue Tracing platform is clearly gaining recognition and third-party validation, including implementations with:

  • Implemented Into the Las Vegas flagship properties of a Global Hospitality company (July 23, 2020)
  • Invited by NCAA DIV 1 BIG EAST CONFERENCE To Present Solution For 11 schools (August 17, 2020)
  • Partnership with BDG sports to deliver NBA, NHL, NCAA and PGA Sporting Events. (August 13, 2020)
  • Implemented By University Of Houston  (September 16, 2020)
  • Loop Insights Signs $1,930,000 USD License Deal with Austin, TX Based CasaPerks (September 28, 2020)
  • Selected as the Premier Venue Tracing and Fan Engagement Solution for NCAA College Basketball “Bubble” in Las Vegas (October 8, 2020)

For more information about the company, please check out the Loop Insights hub on AGORACOM.

Primo Nutraceuticals, a player in the hemp space pivoted early in the pandemic to sell their Primo Lemon Hand Sanitizer in Amazon’s Personal Safety & Household category. The company further solidified its move to PPE by entering into agreement with Duquette Consulting LLC, a company owned by Dan Duquette.

Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers (https://en.wikipedia.org/wiki/Dan_Duquette). Dan Duquette has joined forces with Primo Nutraceuticals to partner in the development, sourcing and the global supply of personal protective equipment products.

The company has been issued a Medical Device Establishment License from Health Canada.The MDEL is a license issued to companies for the activities of manufacturing, importing and distributing of all four classes of medical devices for human use in Canada. These classes include; nitrile gloves, N95 surgical masks & KN95 masks, surgical gowns, respirators and testing kits to name a few.

The PPE Distribution Market worth $28.9 Billion by 2025 in North America and E.U

The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.

For more information about the company, please check out the Primo Nutraceuticals hub on AGORACOM.

Thanks for reading and discovering these great small cap companies. Please be sure to visit the AGORACOM Small Cap Coronavirus Covid-19 company gateway often to stay up to date with new companies at:

https://agoracom.com/portal/Small_Cap_Coronavirus_Covid-19%20

Primo Nutraceuticals $PRMO.ca Enters into a Binding LOI to acquire 100% of the Assets of Full Spectrum Biosciences Inc. $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 10:28 AM on Thursday, November 12th, 2020
  • Announced that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company
  • FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops
  • The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement

VANCOUVER, British Columbia, Nov. 12, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) is pleased to announce that it has signed a binding letter of intent (“LOI”) with Full Spectrum Biosciences Inc.(“FSB”),a Colorado company.

FSB is an intellectual property (“IP”), formulation and white label provider that has conducted sales via e-commerce, online, Amazon and doctors’ offices within the United States offering popular CBD, CBG and Hemp oil extract products like RehabRx and Hemp Pops. The Company will be acquiring the assets and inventory of FSB. The LOI is legally binding and subject to the negotiation of a definitive agreement (the “ Definitive Agreement ”).

TERMS OF THE TRANSACTION

The Company will acquire 100% of the revenue generating assets including the web sites for the popular CBD, CBG and Hemp oil extract products like RehabRx, ( www.rehabrx.com ) and Hemp Pops, ( www.hemppops.com ), the current inventory and the sales and distribution networks that have generated approximately $25,000 to $30,000 USD in monthly revenues since 2018 (the “Transaction”). Gross margin is estimated at 30%.

The consideration for the Purchase will be stipulated in the form of a number of common shares of PRIMO (the “Consideration Shares”) at a per share price equal to the volume weighted average price of such shares on the Canadian Securities Exchange over a 15-day period ending on the day such Consideration Shares are required to be issued (“15 day VWAP”). The consideration paid by Primo to FSB for the Transaction shall be based on an independent valuation of the Assets by a Third Party Valuator. The valuation is currently in progress.

There will be no Change of Control or Fundamental change of business. The Transaction will be subject to review by the parties’ tax, corporate, and legal advisors prior to Closing. The senior management team of PRIMO will consist of those officers presently appointed by the board of directors of PRIMO and shall remain the same.

About Agritek Holdings Inc. and Full Spectrum Biosciences

FSB is a licensed Colorado Corporation which is a wholly owned subsidiary of Agritek Holdings Inc. existing under the laws of the State of Delaware as a “C” corporation, and a publicly traded company on the OTC Markets under the symbol “AGTK” (“Agritek”).

Agritek Holdings, Inc. ( www.AgritekHoldings.com ), is a fully integrated, active real estate investor and advisor of white label brands in the legal cannabis sector. Specifically, Agritek Holdings provides strategic capital and functional expertise to accelerate the commercialization of its diversified portfolio of cannabis related real estate holdings. The hemp based raw material and products produced at facilities owned by Agritek Holdings and leased back to licensed operators are then used for retail branded CBD, CBG and Hemp oil extract products produced by its subsidiary Full Spectrum Biosciences presently sold via e-commerce, online, Amazon and Doctors offices within the United States. Brands include RehabRX , Hemp Pops, MD Vapes , and multiple white labeled brands. Agritek Holdings Inc. does not directly grow, harvest, or distribute or sell cannabis or any substances that violate or contravene United States law or the Controlled Substances Act

“REHAB RX” – Pain Cream, Tinctures, and Gummies; www.rehabrx.com

“HEMP POPS” – CBD Infused Lollipops, Ice Popsicles; www.hemppops.com

Rehabrx.com and Hemppops.com are owned and operated by Full Spectrum Biosciences, Inc., a Colorado corporation with offices in Colorado.

The Global CBD Market

The global CBD market is expected to reach USD 146.4 billion by the end of 2025, according to a new report by Grand View Research, Inc. Growing adoption of marijuana in several medical applications such as cancer, mental disorders, chronic pain and others is expected to propel revenue growth in near future.

Richard Cindric , CEO Comments:

“We are extremely excited to be signing a LOI with Full Spectrum. Gaining FSB’s IP, formulation, white label resources as well as it’s already developed brands like RehabRx and Hemp Pops is a major milestone for the company. As we enter the US nutraceutical market with this acquisition, we believe FSB’s assets compliments our nutraceutical line of products very well. We look forward to working with the FSB team, as well as the introduction of possible future acquisitions.”

Michael Friedman, CEO of Full Spectrum Comments:

“I am pleased to deliver on our promise to the Agritek shareholders that our wholly owned subsidiary Full Spectrum Biosciences has entered into this asset purchase agreement with Primo Nutraceuticals. By having access to both the Canadian and US public markets through Primo, we can work to build our company in both jurisdictions and bring greater value through our combined management teams and contacts for our wellness brands. Our recently announced test pilot program with Biomedican (www.Biomedican.com) using proprietary yeast for synthetic cannabinoid profiles in my opinion will propel our combined companies to an entirely different level within the nutraceutical space and allow us to compete as a biotech within the wellness sector under our new parent company Primo Nutraceuticals”, stated B. Michael Friedman, CEO Agritek Holdings Inc.”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’smanagement is in the process of building a corporate road map to further vertically integrate the Company; specifically, by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Richard Cindric
CEO and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com

www.twitter.com/prmonutra

www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

VIDEO – Primo Discusses MOU For Exclusive Rights to Sell Rapid COVID-19 Test Kits In Canada + Upcoming Spinout of Marianna Naturals

Posted by AGORACOM-JC at 5:52 PM on Friday, October 30th, 2020

Welcome to be on the press release a production of AGORACOM in which we speak to small cap management about their company with us today happy to have him back Richard Cedric is managing director at Primo Nutraceuticals trades on the CSE under the stock symbol P. R. M. O. and 4 friends the US under B. U. G. V. F. now for those who knew the story there’s been a lot going on a lot of re position going on at the company our basic couple these are helping their their their funding the rapid growth of production process retail and branding of cannabis and non cannabis natural health products being important for this off for this purpose that they’ve invested several brands they’re pursued partnerships with retailer distribution companies in Canada the U. S. they got a spin out that’s common they’ve got there M. D.E. L. that’s our medical device License and that’s important because the press release the may possibly talk about today is a Primo signs and amble you for the exclusive rights to sell the rapid Covid 19 test kits in Canada. These are the colloidal gold method Richard welcome back man. Hey thanks for having me great intro right up. Well look Hey that look above the first thing people said people think about when they see something like this is saying all now somebody else trying to get to the Covid19 space but this rapid test it is currently registered with the with the FDA and it’s got its C. E. declaration with with the European community as it are and as has already been operating in China so before we get the details of the deal what is it what do these mean exactly and why is that important to stopping the credibility of you guys bring in have the exclusive rights to this test well the first thing that that we did that brings credibility to us is establishing and getting our medical devices license and our procurement number from health Canada so we could go ahead and and actually import and and submit products like this to help Canada for approval so that’s the first step I mean a lot of companies like Hey I I got this test yet we’re going to be selling it you’re the U. S. with the F. B. through the FDA approval and so forth we’re not we’re not even talking about that we have to be approved first by getting a medical devices license you for health Canada will even look at us so that medical devices license allows us to import and shipped out gloves and N95 masks gloves and testing kits and  it’s only I can go sign up for this.  Articulate behind license first and what allowed us to get the medical devices license is because we had our natural health product number from health Canada which was issued before the medical devices license so there was a trail here leading up to this and it had everything to do with capitalizing on the medical devices license industry given this you know sadly to say this pandemic that is is happening but this is our way of trying to help out in and bring these testing kits to fruition so this particular testing kit was used in during the largest outbreak in China back in February so this test kit has been used by the CDC. It was basically donated to hospitals the CDC distributed in the mostly severe we infected areas and it already comes with clinical trials so the. Health Canada is gonna be requesting any company that is submitting a test kit to have clinical trials and there’s probably about 10 to 15 maybe 20 of them who have submitted a similar test kit or a test kit but not like this because these clinical trials have already been completed almost a year ago where other companies submit application are in the midst of clinical trials so we feel that we’re we’re gonna be out pushed to the top of the line only because clinical trials of already been completed S. all I can is the Guinea pig because it’s sold in other countries already right now once you name those often let’s talk about what that means yeah at present Iran Italy and the United States and other red zone our countries are already using it and obviously coming out of China who seem to be the leader in providing a direction on how to how to combat this cold it will be 19 pandemic is is relevant other companies are actually in the U. S. you know I’ve come up with the product they develop it in the U. S. and now they’re in clinical trial phase right so again we’re idea there behind you technically because this product already has a clinical trials ready to go that’s right that’s right clinical trials of. So part of this is you need to get product license approved by health Canada at that point you’ll have official dealer distribution distributor status with with your Chinese partner you got that M. D. L. we know that so that put you like you said probably near the top do you have an ETA for how long it might take to get this approved by health Canada and and W. W. get even what’s the probability is 5050 is a very high degree of probability what do you guys seeing as investors in the world don’t know you know if these things are getting approved and or what right. Okay so from what we’ve been made aware of is that there’s been one test kit approved so far in Canada and the reason why we and we should be hearing back anywhere from 15 to 25 days as to if we’ve been approved and the reason why we feel that we would be ahead of the line is given our clinical trials right and with that we were do you attain those objectives of of having clinical trials it was a win would you guys submit when you guys submit to health Canada last week it was a couple days after we announce the PR all right so you talk about last. Right. Well it’s October 23 so you talk and let’s say your worst case there are 25 days talk about November 20 give or take time yeah in worst case yeah and mid November we should know if we have or haven’t gotten it I really don’t see why we wouldn’t get it if we are past clinical trial phase but you never know and it’s a high I would say maybe 90-99 percent believe that we might get it because that’s what I’m being told what’s slowing down these companies is that they don’t have their clinical trials completed right right and you guys have got a dispute in the field the target it reduce the rand in Italy in the US over pretty big hot zone so I gotta figure you know health Canada have a problem if they’re already being used there Richard let’s assume you guys got it okay first second half the battle is getting a license like this are you know getting approval getting a partnership  you guys are are teaming up with this you are with with the company is great Neo-Nostics. You get it it’s already go how the other half the battle is how do you make money from it so what I mean by that is if you can answer what’s the marketing plan how do you get this out there with the price points you know what the numbers look like what because you guys I’m sure before you came down this path I’ve probably run some numbers maybe you can give us an idea of where you guys looking at. Okay so numbers wise we have out like like I said we’d be the same the. Product license and distribute their official dealer in Canada there’s 500000 units put aside for us the numbers are pretty big if we’re talking about $50 or 25 to $50 per her up unit you know we’re we’re in the $25000000 range right so around there and I mean the margins are yet to be discovered but gross income that we’d be sharing with Neo-Nostics is north the $20000000 range or all of them all right. Are you trying to be more B. 2 B. are you going to have this you’re going to go up. No that’s. Both. I think right away what we’ll do is contact the distributors that are already you know in that in that framework as well as bring on people to do the B2 B. I mean we’ve got we’ve got actually an ad on indeed for these these types of positions to be filled and we’re doing a financing at $0.10 for $5M to basically be able to follow through with getting these products overboard over over to our shores and then distributed effectively so we’ll be doing a combination of both will let the distributors know that we’ve got this product for sale as well as lead but the large institutions like airports schools and government German agents know that we’ve got this test kit available and approved by health Canada. The research have you start to reach out to them just to kind of you know just in case yeah I I actually in the approval process there was a a section there that basically would let all the German agents know that we’ve been about this particular product has been approved by health Canada all right all right so you know yet what’s the feedback and kind of seeing I’m curious you know are people saying Hey guys once you get this will will definitely want to be taken orders or would use would you stand out we’re we’re talking specifically to schools as well as hospitals and we’re basically getting quoted up 50 thought looking for quotes are 50000 products at a time that’s so far been our largest request for proposal was 50000 units so 10 percent of what are what are actual inventory would be so I think this thing is going to fly off the shelves like one mining company alone which would be interested in a 50000 units because these units are disposable right it’s similar to a pregnancy test your your right **** on the finger draws a little bit of blood and within a couple of minutes you’re you’re aware of what what do you have it or not and there’s a video on the link to the press release of your data shows you how the product works and that’s available for everybody to see it all yeah it was the second to last press release. . But that probably start it went in to add George’s that further back anticipating this we hired a gentleman by the name of Dan Duquette who’s an ex MLB executive and entered the PPE space are a little bit sooner than we did but given his contacts with like you know individuals that are in government positions you know he’s going to be he’s an example of the kind of people that were looking to join the team to help get rid of this casket worker remote the Tuscan. All right so let’s sit back on that that’s a great overview and let’s wait for mid November to see where hopefully you get that first as a Canadian I hope you get that because a citizen would be great to know look I’ve got family I’ve got friends and yelled in in Ontario their backlog 2 or 3 weeks almost doesn’t matter if you get if you get a result now if it’s if you find out you’re positive the but the tells of 2 weeks ago you price front the 0people anyways so right to have it be great to know that these these will be available yeah so and then secondly as a shareholder absolutely right B. you know because so let’s wait till mid November I have our fingers crossed that that happens for both citizens and for shareholders all the other peace news I want to talk about is a pure primo shareholder today or rethinking become approval shareholder you’re going to get our share in Marianna you know what we talk about that and tell us where it’s at yeah for sure so back on April 29 we signed a definitive agreement to help assist beauty kitchen really is the company going to be course public but eventually representing a beauty kitchen so yeah you know we started out on April 29 and at the same time Joel who’s one of our directors was the is the CEO of Marianna he’s been working diligently and so free up pushing this through so it was issued we put out a press release actually yesterday that it retained a transfer agent and has secured its number so that shows that we are very close to this thing trading I think it’ll be trading mid to end of January but you know there’s no reason to wait so yeah basically the ratio would be for every share that you own in primo you’ll get a free share of Mariana and that’s not and that’s saying something because people got a pretty tight share structure right. Yeah we’ve only got that right now we’ve got 10.5m shares outstanding up until January where we will have a total of about 23 to call the 24000000 shares out by mid January so yeah and the mean time you know if we do get this this approval and with only 20M shares outstanding and 6M in the float I see companies with those types of ratios get into the tent you know multiple up 5 to 10 points right so this is at no time to wait on when you’re thinking about getting into the stock that’s only got 10000000 shares in this trading at $0.12 yeah that that yeah that’s fantastic and tells a little bit about the about the business that’s going to be underlying you know the Marianna. We got the bill the underlying business of Marianna to get his beauty kitchen so beauty kitchen is a business that has been around since 2014 she was basically became popular by well I live streaming videos where she was taking products that you find in your  kitchen cabinet and make up you know any type of cosmetics lipsticks and so forth beauty products in general and it took off so she’s developed a line of a product’s Marianna core and beauty kitchen and Marianna’s objective is to add the CBD component to our beauty kitchen’s product line but you know that doesn’t stop the company from possibly doing a a a you know a small takeover of beauty kitchen’s existing revenue shares so that’s something to look at so it’s really you know when you talk about Marianna natural court it’s the subsidiary of beauty kitchen and beauty kitchen is all over the internet for products and so forth so we’ll be all. This is that’s brought into the public company hello hi or the network AV I know I believe about it over a period of time Marianna could possibly become beauty kitchen or vice versa beauty kitchen will end up being the buckle of with depending on how much what percentage is required but similar to what we did with the with thrive wellness 39 percent you know interest is probably something that Marianna might as well might do as well in beauty kitchen. Yeah at some point be great what we do is maybe after November 15 is you know just to corporate data relays out each 1 of these because you guys are you know you kind of funding these companies are investing in summer brand partnerships would be greater because you know the the after after primo went through some good restructuring it’s really starting to set itself up for a winning it all winning structure for 2021 would be great if we agree with that I mean that was the reason for the name change so we can capitalize on not only the THC and CBD market but the natural health market and it just opens up a wide variety of options that we have and even prior to. This acquisition of the up or M. O. U. we announced a cut to press releases to do with the mushroom market you’ll see that David no shot is an individual that has was granted the ability to do research on Gino typing it Kimmel typing of CBD products so now he’s going to come on board with us and do the same type of of research for the mushroom space and hopefully you know we could be one of the companies that gets the second micro dosing license so because we’re a nutraceutical company it’s allowed us to do that and our short term objective. Is is the seat is the PP space and our long term objective is you know sticking to the natural nutraceutical space and you know developing the this I. P. through the psilocybin with David no shot as well as you know with a lot of these marijuana companies you can get get into a project on pennies on the dollar but he’s on the dollar and we’re looking at farms right now which can encompass art sheet C. B. D. and continue on with the P. P. as a nutraceutical company right well great that you got an issue for both the short term like this M. O. U. for the rights of the covert 19 rapid test EDM term yeah like Marianna and and the long term through what you’re doing with the R&D. and the silence of bins and and and the psychedelic side I think that’s a great combination for a small cap company well you know what another thing is to it was pretty critical changing the name to primo and becoming a nutraceutical company because we’re getting contact from trivago’s in the US wanted to piggy back in doing similar what we are doing with Marianna so once we get Marianna through the goal line we’re gonna be doing a lot more spin outs because we was successfully done one and we know what to do because you and I both know lot of companies announced they’re doing a spin out and a lot of them don’t even come through so we want to get this one through the finish line show that we’re a company that actually does what they say that they’re going to do and and and continue on with identifying you know nutraceutical brands that can fall under the cream on on Broadway and primo is a terrific branding name when you consider media. Yes because what do you ask what for when you’re looking for a a a quality product you ask if it’s primo give me the primo stuff baby primo stuff baby now it’s great to know I looked at how to get to know that you got that one as a shareholder that I am sure older people are watching that you’re going to get a one for a one for one spin out that’s just almost too good to give half right we don’t and and and again we just announced that they’ve secured the transfer agent because they received . Nothing says that we are anticipating trading our common shares swiftly in the future than that so yeah right yeah absolutely I mean still has to happen look for the covert 19 does still got to get the health Canada for the spin out that’s going to happen but the fact that they’re both on track and they’re both locked up. On the menu you’re not just taking shots in the dark here which is great I’ll I’ll be honest with you Marriott Corp would be trading by now. But we’ve been you know the rollback caught you know because the delay and all we’re waiting on is basically calling our AGM which is we’re weeks away from that once that happens you know we’re we’re basically at the goal line with the spin out. Set number great 2021 man. 2021 great see the you guys came through some turbulence earlier in the year and now you know you’re really getting the ship on the right direction and can’t wait to have you back Richard. Yeah thanks George appreciate your guys support and again remember we’re out we’re doing a financing here $0.10 so if any of your people are interested I’m sure they can contact us on the website or Regis any by email got a great story I’m assuming you’re in the private placement also means that you’re going to get you know that and that share in Marianna right off get looks like you’re actually securing your your share Marianna because because yeah you’re you’re participating in the P. P. but that is a guaranteed if you did you participate in the PP you secure your position America.  You can watch and or if you listen by podcast to Richard Cindric managing director primo nutraceuticals trade on the CSE under the stock symbol P. R. M.O a fantastic name it’s the Primo name and look if you want more information to get kind of caught up with the story because you’re probably discovery again the company had to go through some restructuring but did a great job of pivoting you know seeing it more problems in the market pivoting out and and really doing some great things now as you heard from Richard self get to court get too bored calm start your research thank god over the primo site do more research there hope you discovered your next great small cap companies thanks for joining us everyone have a fantastic day see you next time.

VIDEO – Primo $PRMO.ca Discusses MOU For Exclusive Rights to Sell Rapid COVID-19 Test Kits In Canada + Upcoming Spinout of Marianna Naturals $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 4:42 PM on Wednesday, October 28th, 2020

Primo Nutraceuticals Inc. $PRMO.ca signs a Memorandum of Understanding for Exclusive Rights to Sell Rapid (Colloidal Gold Method) COVID-19 Test Kits in Canada $MRS.ca $FTI.ca $MMM $HON $MSA

Posted by AGORACOM-JC at 8:07 AM on Wednesday, October 21st, 2020
  • Signed of a Memorandum of Understanding with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).
  • Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020
  • Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

VANCOUVER, British Columbia, Oct. 21, 2020 – PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF ) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (” PRIMO ” or the “Company”) announces the signing of a Memorandum of Understanding (MOU) with Neo-Nostics(Suzhou) Bioengineering Co. Ltd. Of Su Zhou City, China (“Neo-Nostics”) as the official trade representative for Neo-Nostics ™ with the exclusive rights to apply for licensing and to market and sell the following COVID-19 production Canada: Neo-Nostics 2019-nCoV IgG/IgM Rapid Test Kit (Colloidal Gold Method) (Test Kit).

The Memorandum of Understanding between Primo and Neo-Nostics ™, is effective as of October 13, 2020. Upon successfully receiving product license and approval by Health Canada, Neo-Nostics ™ will grant Primo with “Official Dealer/Distributor Status” in Canada.

The Neo-Nostics2019-nCoV IgG/IgM Rapid Testing Kit is currently registered with the FDA. Primo will be submitting the application for approval to Health Canada immediately. Neo-Nostics ™ has committed to supporting Primo’s efforts to obtain and maintain all necessary certifications and approvals for the sale and marketing of the Test Kits in Canada by granting access to all necessary documentation and clinical studies concerning the Test Kits.

Follow the link for a video demonstration: http://www.neo-nostics.com/skin/images/mp40.mp4

About the Neo-NosticsRapid Test Kits

The Neo-Nostics 2019-nCoV Antibody Detection Reagent Kit (Colloidal Gold Method) has the advantage of rapidity, convenience, high accuracy, and can make up for the shortcomings of professional requirements, time consumption and low positive detection rate of PCR nucleic acid detection, and can be used as an important supplementary detection method for the diagnosis of coronal pneumonia.

Through detection and calculation, it is found that the comprehensive accuracy rate of the Neo-Nostics2019-nCoV IgM Detection Reagent is higher than 95%.

During the worst period of the epidemic in China, the reagent kit was donated to hospitals and the CDC in the most severely infected areas of Hubei for clinical auxiliary diagnosis. At present, the verification reports made by three clinical units prove that the positive detection rate of clinically confirmed cases has reached 92%, which has exceeded the general detection effect. Not only negative or positive results can be detected, but also the early, middle and or recovery period of virus infection can be distinguished by the positive strength of IgM or IgG.
Source: Clinical study report conducted by the Institute of Virology, in the capital city of Hubei, China and The Chinese Academy of Sciences in Beijing, China.

DISCLAIMER: “The Company is not making any express or implied claims that it has the ability to eliminate, cure or contain the Covid-19 (or SARS-2 Coronavirus) at this time”.

Clinical Applications of Reagents

This reagent has been used by professionals in China since February 2020 in an area that was the hardest hit and impacted most severely by COVID-19, in the form of clinical auxiliary diagnosis.

The reagent kit was clinically verified by several professionals, hospitals, and universities respectively, and corresponding reports were used as reference.

At present, Iran, Italy, the United States, and other red zones have already adopted it . Neo- N osticshas CE declaration of conformity, local records of European Authorized Representative and FDA records in the United States.

View the FDA records here: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfrl/rl.cfm?lid=669386&lpcd=QKO

Advantages of the Colloidal Gold Method

1. Quick – 10 minute results.

2. Simple – The detection results can be determined by the naked eye.

3. Sampling – Only fingertip blood or venous blood is required for detection.

4. It is suitable for clinical auxiliary diagnosis.

About the COVID-19 Detection Kit Market

According to a new report by Grand View Research, Inc., The global COVID-19 detection kits market size is projected to reach USD 4.63 billion by 2027 . The COVID-19 pandemic has posed several challenges to the global healthcare systems. As a result, companies are ramping up their production process to meet the demand or kits and reagents as well as at-home tests, thereby driving the market revenue. https://www.grandviewresearch.com/industry-analysis/covid-19-detection-kits-market?utm_source=prnewswire&utm_medium=referral&utm_campaign=hc_15-sep-20&utm_term=covid-19-detection-kits-market&utm_content=rd

Mr. Joey Zhou, CEO of Neo-Nostics(Suzhou) Bio-Engineering Co. Ltd. Comments:

“Penetrating the Canadian market with our advanced and highly effective test kit will be a great milestone for our company as well as for the fight against theCOVID-19 virus. We are pleased to be partnering with Primo Nutraceuticals and their team”

Richard Cindric, CEO of Primo Comments:

We are looking forward to working with Neo-Nosticsto provide a premium quality product. We anticipate the relationship to grow and look forward to updating our shareholders with our future milestones.” It is important to note that receiving the MDEL license from Health Canada has opened up a plethora of opportunities like this one which will result in revenue in the immediate short term for Primo and its shareholders.”

About Neo-Nostics(Suzhou) Bioengineering Co. Ltd.

Neo-Nostics ™ (Suzhou) Bioengineering Co., Ltd. which was established in 2015, is a professional company specialized in researching, developing, manufacturing, and distributing advanced medical instruments and in-vitro medical diagnostic products. Their products are usually used for fertility tests, infectious diseases tests, drugs of abuse tests, alcohol saliva tests, urinalysis reagent strips, cardiac marker tests, tumor marker tests, food and safety tests and animal disease tests.

To learn more about Neo-Nosticsplease visit: http://www.neo-nostics.com/en/

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the company; specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals $PRMO.ca Engages MedCan Biotechnologies to Conduct Chemo typing & Geno-typing Studies of #Psilocybin Mushrooms $AION.ca $PLNT.ca $SHRM.ca $CMPS

Posted by AGORACOM-JC at 11:32 AM on Wednesday, October 14th, 2020
  • Entered into a non-binding letter of intent with MedCan Biotechnologies Inc.
  • MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms

VANCOUVER, British Columbia, Oct. 14, 2020  — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVF) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“PRIMO” or the “Company”)

Primo Nutraceuticals Inc. has entered into a non-binding letter of intent (the “LOI”) with MedCan Biotechnologies Inc. (“MEDCAN BIOTECH”). MEDCAN BIOTECH will act as a consultant to conduct a chemo typing (Chemical Analysis) and a genotyping (Genetic Analysis) study of up to 5 strains of Psilocybin mushrooms (commonly known as Magic Mushrooms).

Terms of Engagement

Health Canada (HC) has recently shifted towards psychedelic-assisted psychotherapies in safe, controlled environments as acceptable treatment options.

Pursuant to Section 56 exemption from the Canadian Drugs and Substances Act to treat anxiety associated diagnoses,MEDCAN BIOTECH will apply to Health Canada to receive approval under the Controlled Drug and Substances Act to allow MEDCAN BIOTECH to conduct research in order to effectively standardize the extraction of psilocybin from mushrooms.

The Health Canada permit by MEDCAN BIOTECH will allow to develop and license intellectual property (IP) exclusively for further product development by PRIMO via chemo-typing and geno-typing of 5 different mushrooms to understand their properties.

MEDCAN BIOTECHwill proceed to patent methods of analysis and results on behalf of PRIMO, whereby data generated will be used in the production of nutraceutical products.

All IPa nd products developed as a result of the analysis will become the property of PRIMO for their exclusive use.

Psychedelic research focused on psychedelic medicine and psychedelic drugs have demonstrated that these substances have potential for treating ailments including anxiety, addiction, depression, substance dependency, attention deficit hyperactivity disorder and even post-traumatic stress disorder.The data produced can be used to generate premium natural health mushroom nutraceutical products. Genotyping can be used for the identification and labeling of different varieties of psilocybin mushrooms.

About MEDCAN BIOTECH

MEDCAN BIOTECH is an all-natural solution research and development company to better personal wellbeing.MEDCAN BIOTECH has already researched and formulated a range of cannabinoid products that combine with the multi-faceted cannabinoid component with other natural active ingredients to create products for Sleep, Mood, Mind and Pleasure presented online at: www.medcanbiotech.com

Founder, Dr. David Noshad is a part-time faculty member at British Columbia’s Thompson Rivers University as well as President of Bio-Act Technology which specializes in research and development consulting with respects to life-science, cannabis and agri-food industry.

In 2010, Dr. Noshad served as Principle Co-Investigator with the UBC’s Faculty of Pharmaceutical Sciences in cannabis pharmacology; characterizing cannabinoids and terpenes in cannabis and Humulus. The projects included in vitro culture techniques, biochemical analysis, molecular biology and genomic techniques.

About the Psychedelic Market

In the first half of 2020, US$150 million was raised by psychedelics-focused companies. The research group projects that the global psychedelics industry may reach a total value of US$7 billion by the year 2027. According to: https://reportonpsychedelics.com/

Richard Cindric, CEO of Primo Comments:

“It is an honor to have Dr. Noshad collaborating with us. We are confident his qualifications and experience in characterizing cannabinoids and terpenes in cannabis will translate into the development of IP focusing on psilocybin treatments for neuropsychiatric diseases.

By investing resources in functional mushroom beverages with Brujera Elixer, as well as developing an IP on psychedelics with MedCan, we will be able to introduce premium natural health mushroom products toboth thepsychedelic and non-psychedelic market places.”

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License(MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

AndyJagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan Sarkozy, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals Inc. $PRMO.ca Signs Letter of Intent with Brujera Elixirs Inc. to Formulate 4 Innovative Adaptogenic Mushroom-Infused Beverage Products

Posted by AGORACOM-JC at 9:41 AM on Thursday, October 1st, 2020
  • Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.
  • Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020

VANCOUVER, British Columbia, Oct. 01, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo Nutra” or the “Company”) Further to the Company’s news release dated May 22, 2020 announcing that Primo Nutra received its Natural Product Number (“NPN) from Health Canada, the Company has decided to continue down that path by announcing that it has entered into a non-binding letter of intent (the “LOI”) with Brujera Elixirs Inc. (“Brujera”) to formulate an exclusive line of 4 “Innovative adaptogenic mushroom-infused” beverage products for the natural health and wellness market.

Product development and steps for final formulation will commence immediately upon signing of the definitive agreement with Brujera; which is expected to occur on or before October 30, 2020.

The specific types of functional mushrooms which will be used in formulating Primo Nutra’s exclusive beverages will be: Reishi , Cordyceps, Lion’s Mane and Chaga.

The Company was granted its first NPN ( 80099466) on May 22, 2020 for their lemon hand sanitizer. Primo Nutra will be focused on introducing 8 different natural health products to Canada’s health and wellness market.

About Brujera Elixirs Inc.

Launched by award winning B.C. master mixologist, sommelier and entrepreneur Kelly Ann Woods, Brujera is a house of brands which currently includes Boozewitch (sober-curious mixers) and State B Cannabis Beverage Co.Ms. Woods is an entrepreneur who has founded multiple companies in the CBD, cannabis, alcohol and non-alcohol beverage industry. In the last year, Kelly was named the 2019 RBC Canadian Woman Entrepreneur of the Year Award for Micro -Business Award ( https://www.youtube.com/watch?v=oLi9JSnhJ64 ). Woman of the Year from BC Business in addition to a CANIE Woman Entrepreneur award.

Nicknamed the “Boozewitch,” Quebec-born Kelly attended CEGEP in Montreal with a focus on theatre and worked as a flight attendant for Air Canada before moving to the West Coast. She spent years honing her drinks skills as a sommelier and doing hospitality work, all the while experimenting with beverage formulation. She is actively bringing a cannabis beverage to the US and Canadian markets under the name State B and opening an oceanfront wine bar in Squamish with a team of accomplished women in hospitality.

TERMS OF THE TRANSACTION

The LOI was signed on July 14, 2020. Pursuant to the LOI Primo Nutra and Brujera will seek to enter into a Definitive Consulting Agreement whereby Primo Nutra will create white label mushroom infused drinks for distribution in Canada and international markets while Brujera will create unique exclusive formulations for Primo Nutra’s mushroom-infused energy shot drinks.

Richard Cindric, CEO of Primo Comments:

“Ms. Woods experience in formulating functional CBD, cannabis, and alcoholic beverages is what we are looking for in a white-label partner. We are confident she is the right partner to introduce a mushroom based energy drink to compete with brands like Boost and Ensure. We are in a better position now than a year ago to peruse a line of energy drinks, as it was important to get a NPN number from Health Canada first.”

Kelly Ann Woods, CEO of BRUJERA Comments:

“We are pleased to be aligning ourselves with Primo for this line of adaptogenic mushroom drinks. At a time when immunity and cognitive function are at the forefront of people’s minds, this product is sure to be one in many people’s daily regime.”

The Global Energy Drink Market

According to Allied Market Research, the global energy drinks market size was valued at USD$53B in 2018 and is expected to reach USD$86B by 2026. https://www.alliedmarketresearch.com/energy-drink-market

About Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo Nutra’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it had received its NPN and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net
www.statebelevate.com

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

Primo Nutraceuticals $PRMO.ca and Dan Duquette, Former MLB Executive, Sign Definitive Agreement to Capitalize on Primo Receiving an MDEL License from Health Canada and announces Stock Option Grant

Posted by AGORACOM-JC at 9:09 AM on Thursday, September 24th, 2020
  • Further to the Letter of Intent with Duquette Consulting LLC referred to in the Company’s news release dated September 1, 2020 the Company has signed a Sales & Marketing Agreement to consummate the transaction
  • Primo expanded into the Canadian Medical Devices and personal protective equipment (“PPE”) markets, the Company pursued and was granted a Medical Device Establishment License
  • Primo and Duquette Consulting will work towards securing contracts and purchase orders for PPE equipment that includes N95 surgical masks, KN95 masks and surgical masks

VANCOUVER, British Columbia, Sept. 24, 2020 — PRIMO NUTRACEUTICALS INC. (CSE: PRMO) (OTC: BUGVD) (FSE: 8BV) (DEU: 8BV) (MUN: 8BV) (STU: 8BV) (“Primo” or the “Company”) is pleased to announce that further to the Letter of Intent (the “LOI”) with Duquette Consulting LLC (“Duquette Consulting“) referred to in the Company’s news release dated September 1, 2020 the Company has signed a Sales & Marketing Agreement to consummate the transaction.

As Primo expanded into the Canadian Medical Devices and personal protective equipment (“PPE”) markets, the Company pursued and was granted a Medical Device Establishment License ( MDEL ) . The Company must comply with the regulations of Health Canada relating to manufacturing, importing, distributing and selling medical devices in Canada in order to receive a MDEL. Primo has demonstrated to Health Canada that the Company has met the regulatory requirements mandated of a MDEL license holder.

Primo and Duquette Consulting will work towards securing contracts and purchase orders for PPE equipment that includes N95 surgical masks, KN95 masks and surgical masks. Primo intends to acquire any and all additional necessary licensing and will take any additional steps required to import and/or distribute all four classes of medical devices in Canada, which include nitrile gloves, face shields, surgical gowns, respirators and testing kits.

TERMS OF THE TRANSACTION

The Sales & Marketing Agreement was made effective as of the 9 th day of September 2020.

Primo, a reporting issuer on the CSE was required to obtain an MDEL license from Health Canada to authorize the parties to sell and distribute PPE products for government contract purposes and to commercialize any related opportunities. To consummate this relationship Primo Nutraceuticals Inc., obtained the following approvals;

  1. a Government Procurement number; 806756235PG0001
  2. an Interim COVID-19 site license number; COV0950 and
  3. a Medical Device Establishment License number; 14815 .

Primo will assist Duquette Consulting in bidding on government tenders in Canada.

P PE Distribution Market worth $28.9 Billion by 2025 in North America and E.U

The North America and Europe distribution market for PPE is expected to reach US$28.95 M by 2025.

About Dan Duquette & Duquette Consulting LLC

Dan Duquette is a twice named Major League Baseball (MLB) Executive of the Year and former Executive Vice-President of the Baltimore Orioles, General Manager of the Montreal Expos, Boston Red Sox, and Milwaukee Brewers.

Duquette Consulting entered the PPE market by sourcing and selling products and supplies at a government & state level to help in the fight against COVID-19, securing, shipping and recently delivering over 5 million masks to the State of Maryland.
https://www.businesswire.com/news/home/20200727005153/en/Duquette-Consulting—State-Maryland-PPE-Fulfillment

Stock Options Granted

In addition, the Company has granted a total of 2,300,000 incentive stock options to directors, officers, employees and consultants under the Company’s stock option plan, which was approved by the Company’s board of directors. The incentive stock options (the “Options”) are exercisable at $0.15 per share and will expire on September 25, 2021. Following this option grant the Company has 2,300,000 Options outstanding.

Primo Nutraceuticals Inc.

Primo Nutraceuticals Inc. (“Primo” or the “Company”) is dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. Primo has invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo” & “Thrive,” brands and a selection of curated partner brands. Most recently Primo announced that it has received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada.

On behalf of the Board of Directors

PRIMO NUTRACEUTICALS INC.

Andy Jagpal

Andy Jagpal
President and Director

For further information, please contact Zoltan, IR Representative at: 604-722-0305, or; [email protected] .

To learn more about what this news means to the shareholders visit:

www.primonutraceuticals.com
www.twitter.com/Prmoinc
www.thrivecbd.com
www.mariannacorp.com
www.dcppe.net

FORWARD LOOKING STATEMENTS: This news release contains certain forward-looking statements within the meaning of Canadian securities laws. Forward-looking statements are based on the expectations and opinions of the Company’s management on the date the statements are made. The assumptions used in the preparation of such statements, although considered reasonable at the time of preparation, may prove to be imprecise and, as such, undue reliance should not be placed on forward-looking statements. The Company expressly disclaims any intention or obligation to update or revise any forward-looking statements whether as a result of new information, future events or otherwise. No regulatory authority has approved or disapproved the information contained in this news release.

VIDEO: Primo Nutraceuticals $PRMO.ca Discusses Receipt of Medical Device Establishment License (MDEL) from Health Canada, Pivots to PPE

Posted by AGORACOM-JC at 4:55 PM on Tuesday, September 22nd, 2020

Primo Nutraceuticals Inc. (PRMO:CSE) (BUGVD: OTC) (FSE: 8BV) dedicated to funding the rapid growth in production, processing, retail and branding of cannabis and non-cannabis natural health products in Canada and the United States. 

Primo has recently invested in several brands and is pursuing partnerships with retailers and distribution companies in Canada and the United States. 

Primo’s management is in the process of building a corporate road map to further vertically integrate the Company, specifically by way of the “Primo”  & “Thrive,” brands and a selection of curated partner brands. 

Most recently Primo announced that it has received its Natural Product Number (NPN) and it has been issued a Medical Device Establishment License (MDEL) from Health Canada. 

Watch this interview or listen by Podcast on AppleGoogleSpotify or your favourite podcaster.